Drimmunity Secures $40 Million Series B Financing to Advance Solid Tumor Immunotherapies

7Month15Day, Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd. (Drimmunity / Tcelltech), a clinical-stage biopharmaceutical company focused on the development of immunotherapies for solid tumors, announced the completion of nearly 4000"Million US dollars" B Round of financing. This round was led by SDIC Capital, with a well-known insurance company and Hetang Venture following up. It also received strong support from institutions such as Xingye Guoxin Asset Management and Fuzhou Mindu Talent Fund.

This round of fundraising will be mainly used to support the company's core pipeline. TX-103 The clinical development in China and the U.S., R&D of other pipeline projects, global team expansion, and the acceleration of the company's international strategic layout and advancement. BD Cooperation.

Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd. was co-founded by Professor Chen Lieping, a pioneer in tumor immunology, and Professor Huang Gangxiong, an expert in immune cell therapy. The company isTAn innovative biopharmaceutical company with cell immunotherapy products as the core of development.

Core Pipeline of the CompanyTX-103Is the world's first product to enter the registration clinical trial and conduct international clinical trials.B7-H3 CAR-T Cell Therapy Products, for recurrent glioblastoma (rGBM) and other solid tumors. TX-103In the early clinical trials, it has demonstrated excellent efficacy and safety, which can rGBMPatient mOS Significantly prolonged, with a significant increase in one-year survival rate, and good tolerance, it is expected to break through the treatment bottleneck of existing therapies. Currently, globalI `Clinical trial period.`

In addition, based on the founding team's deep accumulation and global leadership in tumor immunology, Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd. is simultaneously developing the next generation of universal-type/In Vivo Cell Therapy and T Cell Connector Platform, striving to build a globally leading platform company in solid tumor immunotherapy.

The founder of the company stated:“This round of financing will strongly accelerate the company's development progress and inject strong momentum into the research and development of various innovative immunotherapies and multiple pipelines.”

References:

[1]Fuzhou Tuoxin Tiancheng Biotechnology Co., Ltd. Completes Nearly 40 Million USD in Series B Financing, Accelerating the Development of Multiple Solid Tumor Immunotherapies

PharmaCube Pro

Insights into Global Biomedical Frontiers

Empowering the Transformation of China's Indigenous Innovation Achievements

Media Cooperation: 15895423126